Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Corbus Pharmaceuticals Hldgs Inc (CRBP)
Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corbus Pharmaceuticals Hldgs Inc 500 River Ridge Drive Norwood MA 02062 USA

P: 617-963-0100

Description:

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Key Statistics

Overview:

Market Capitalization, $K 29,816
Enterprise Value, $K 31,746
Shares Outstanding, K 4,424
Annual Sales, $ 0 K
Annual Net Income, $ -42,350 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -8,780 K
EBIT, $ -44,470 K
EBITDA, $ -42,110 K
60-Month Beta 2.29
% of Insider Shareholders 6.80%
% of Institutional Shareholders 16.73%
Float, K 4,123
% Float 93.20%
Short Volume Ratio 0.28

Growth:

1-Year Return 28.53%
3-Year Return -87.52%
5-Year Return -96.72%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 54.15%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.05 on 08/08/23
Next Earnings Date 11/14/23
Earnings Per Share ttm -11.00
EPS Growth vs. Prev Qtr 51.65%
EPS Growth vs. Prev Year 2.48%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 02/14/23

CRBP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -183.08%
Return-on-Assets % -78.45%
Profit Margin % 0.00
Net Margin % N/A
Debt/Equity 0.85
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 3.08
Book Value/Share 2.16
Interest Coverage -18.88
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar